Gly3-Val-Cit-PAB-MMAE CAS:2684216-48-4 is a cutting-edge drug-linker conjugate designed for the development of antibody-drug conjugates (ADCs) in cancer therapy.
Payloads and Linker modified Payloads
Please leave a message for us or use the following ways to contact us, we will reply to you as soon as possible, and provide you with the most sincere service, thank you.
日本语
한국어
Français
Deutsch
España
Türkiye